At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Enabling a new era in minimally invasive obesity treatment across Europe
Subscribe To Our Newsletter & Stay Updated
